Physicians' Academy for Cardiovascular Education

BET inhibition in cardiovascular disease: A new dawn?

Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

This lecture was part of a CME accredited symposium: 'A novel approach for high CV risk patients with diabetes: The potential of epigenetics' held at ESC 2016 in Rome

Educational information

The educational objectives of this symposium were:

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty & Disclosures

Prof. John J.P. Kastelein is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease

Funding

Supported by an unrestricted educational grant from Resverlogix.

View slides of this lecture